Asset Details
Do you wish to reserve the book?
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Do you wish to request the book?
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
2014
Overview
In patients ineligible for transplantation, the combination of lenalidomide and dexamethasone with lenalidomide maintenance until disease progression achieved significantly improved progression-free survival, as compared with melphalan, prednisone, and thalidomide therapy.
For patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation, the standard therapy is melphalan and prednisone (MP) combined with either thalidomide (MPT) or bortezomib (VMP).
1
–
10
Lenalidomide (Revlimid, Celgene) is an immunomodulatory drug that, in combination with dexamethasone, is a standard treatment option for patients with multiple myeloma who have received at least one prior therapy as approved by the Food and Drug Administration and the European Medicines Agency.
7
–
13
In a randomized trial that included both younger and older patients with newly diagnosed multiple myeloma, lenalidomide plus low-dose dexamethasone was associated with fewer adverse . . .
Publisher
Massachusetts Medical Society
Subject
/ Aged
/ Antineoplastic Combined Chemotherapy Protocols - adverse effects
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Biological and medical sciences
/ Dexamethasone - administration & dosage
/ Dexamethasone - adverse effects
/ Female
/ Humans
/ Immunodeficiencies. Immunoglobulinopathies
/ Male
/ Melphalan - administration & dosage
/ Multiple Myeloma - drug therapy
/ Multiple Myeloma - immunology
/ Pharmacology. Drug treatments
/ Prednisone - administration & dosage
/ Steroids
/ Thalidomide - administration & dosage
/ Thalidomide - adverse effects
